FocusOn Neurology
  • Biozone
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • Myasthenia Gravis
  • Neurofibromatosis
  • hATTR-PN
  • MDA 2024
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights
  • Parkinson's Disease
  • Multiple Sclerosis
  • Migraine Research Library
  • LGS & Dravet Syndrome
  • Tardive Dyskinesia
  • hATTR-PN
  • CIDP Awareness Month
  • Alzheimer's Awareness Month
  • Anticoagulation Reversal Knowledge & Learning Center
  • PNS 2024 Annual Meeting Highlights

Advanced Search

Advanced Search

  • Featured:
  • Biozone
  • Myasthenia Gravis
  • Neurofibromatosis
  • MDA 2024
  • Parkinson's Disease
 

Test Your Knowledge

Back to Myasthenia Gravis Resource Center homepage
  1. Which of the following clinical signs is NOT a typical feature of myasthenia gravis?
  2. Which of the following factors may trigger or exacerbate symptoms of myasthenia gravis?
  3. Individuals with myasthenia gravis should avoid which of the following medications?
  4. Which of the following agents is typically indicated as the initial immunosuppressive therapy to control the symptoms and progression of ocular myasthenia gravis?
  5. Thymectomy is strongly indicated in patients with which of the following subtypes of myasthenia gravis (MG) who cannot tolerate or fail to respond to initial immunotherapy?

References

  1. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med 2021; 10(11):2235.
  2. Blum S, Lee D, Gillis D, et al. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 2015; 22(7):1164-9.
  3. O'Connor L, Westerberg E, Punga AR. Myasthenia Gravis and Physical Exercise: A Novel Paradigm. Front Neurol 2020; 11:675.
  4. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021; 96(3):114-122.
  5. Haroutiunian S, Lecht S, Zur AA, et al. The challenge of pain management in patients with myasthenia gravis. J Pain Palliat Care Pharmacother 2009; 23(3):242-60.
FocusOn logo
  • Articles
  • Multimedia
  • Blog
  • Resources
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More